Sooma
Sooma Medical develops noninvasive brain stimulation treatments, such as tDCS, for depression and chronic pain management, offering medication-free healthcare solutions.
Classification
Profile
Funding
Funding details not yet available.
Compliance
Safe, medication-free depression and chronic pain treatment using noninvasive tDCS brain stimulation to relieve symptoms and reduce clinic queues.
Patients suffering from depression and chronic pain conditions, served through psychiatric clinics and healthcare providers.
Direct sales of tDCS devices and therapy systems to healthcare providers and patients.
Direct distribution to clinics and patients across more than 30 countries, leveraging FDA Breakthrough Device Designation for market entry.
Foremost experts in psychiatry and neurophysiology who collaborate on developing safe and effective treatment options.
R&D for brain stimulation technology, regulatory compliance for FDA and EU approvals, and global distribution logistics.
Proprietary tDCS technology developed over a decade, combined with deep expertise from leading medical specialists.
Developing noninvasive brain stimulation treatments and collaborating with medical experts to create medication-free care options.
B2B2C model supplying devices to clinics and patients, supported by clinical validation and regulatory endorsements.
Competes in the depression and pain management sectors by offering a noninvasive, medication-free alternative to traditional treatments.
High patient queues at clinics and the need for effective, safe, medication-free treatment options for depression and chronic pain.
Team details not yet available.
No investors recorded yet.